Entering text into the input field will update the search result below

Equillium shares rise with response rate seen in acute graft-versus-host disease trial

Mar. 15, 2021 8:44 AM ETEquillium, Inc. (EQ) StockEQBy: Jonathan Block, SA News Editor
  • Full data from Equillium's (NASDAQ:EQ) phase 1b/2 trial of itolizumab as a potential first-line treatment for acute graft-versus-host disease (aGVHD) provided further evidence that the mAb provided a complete response in a majority of patients in 15 days.
  • Also, there was a

Recommended For You

More Trending News

About EQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EQ--
Equillium, Inc.